ClinicalTrials.gg
WithdrawnNCT01125761Updated Nov 3, 2022

Efficacy and Safety of the Association Drugs in Patients With Allergic Dermatitis

A Phase 3 interventional study of dexamethasone 0.5 mg and 1.0 mg clemastine cream and Dexamethasone 0,5 mg cream in Dermatitis, sponsored by Azidus Brasil. Withdrawn at 2 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-03.

Sponsored by Azidus Brasil · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Considering the pathogenesis of several allergic skin diseases to be investigated in this study as well as the pharmacodynamic mechanisms of the association of dexamethasone and clemastine fumarate, it is believed that the components of topical medication may act synergistically in the reduction of signs and symptoms of the diseases in question. Therefore it is expected that the association promotes results significantly superior to dexamethasone alone.

02

Conditions studied

  • Dermatitis

Keywords

  • Allergic dermatitis
03

In context

Dermatitis

238 studies on the registry are indexed under Dermatitis; 33 are open to participants now.

Browse Dermatitis studies →

Lead sponsor

Azidus Brasil is the lead sponsor of 80 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who sign the Deed of Consent (IC) in two ways, by his own free will, agreeing with all study procedures;

    • Patients older than 18 years, any ethnicity, class or social group, regardless of sex;
    • Patients with pictures of dermatoses acute, subacute or chronic, of inflammatory origin and / or allergic, to which it is recommended the use of drugs under investigation topically, such as:
  • atopic dermatitis,
  • prurigo,
  • primary contact dermatitis or allergic
  • urticaria,
  • pharmacodermic,
  • allergic vasculitis,
  • dyshidrosis,

Exclusion criteria

Exclusion Criteria:

  • Patients being treated with antibiotics;
  • Participation in clinical trials in the 12 months preceding the survey;
  • Current treatment with (eg, cyclosporine or methotrexate);
  • Current treatment with phototherapy (UVA, UVB, PUVA and lasers);
  • Use of systemic at inclusion visit or within 15 days prior to inclusion;
  • Topical treatments at the site of acne in the 15 days preceding the visit of inclusion;
  • Presence of any skin condition in areas affected by acne that hamper the evolutionary analysis of the lesion;
  • Presence of secondary infections at the site of treatment, diagnosed clinically;
  • Presence of other eczematous picture, such as nummular eczema, neurodermatitis, seborrheic dermatitis, psoriasis, scabies, and Buckley's syndrome Wiskott-Aldrich;
  • Pregnant or lactating women;
  • Chronic alcoholism;
  • Patients with a history of to any component of the formulas of the products under investigation;
  • Any finding of clinical observation (clinical history or physical examination) that is interpreted by the physician investigator as a risk to the patient's participation in the study;
  • Allergic Dermatosis of moderate or severe that, according to the investigator, is not justified topical.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    dexamethasone 0.5 mg and 1.0 mg clemastine cream

    Drug: dexamethasone 0.5 mg and 1.0 mg clemastine cream

  • Active comparator
    dexamethasone 0,5 mg cream

    Drug: Dexamethasone 0,5 mg cream

Interventions

  • Drugdexamethasone 0.5 mg and 1.0 mg clemastine cream

    Drug page: Dexamethasone

    The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.

  • DrugDexamethasone 0,5 mg cream

    The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.

06

What researchers measure

Primary outcomes

  1. Through clinical examinations, evaluating the efficacy of the cream composed by 0.5 mg dexamethasone and clemastine 1mg compared with the cream of 0.5 mg dexamethasone in improving the signs and symptoms associated with allergic dermatitis.

    Time frame: 14 days

Secondary outcomes

  1. Improvement of the erythema associated with allergic dermatitis.

    Time frame: 14 days

  2. Improvement of the edema associated with allergic dermatitis.

    Time frame: 14 days

  3. Improvement of the extension of lesion associated with allergic dermatitis.

    Time frame: 14 days

  4. Evaluate, through clinical examinations, the effectiveness of the drug association in reducing excoriation associated with allergic dermatitis.

    Time frame: 14 days

  5. Evaluate, through clinical examinations, the effectiveness of the drug association in reducing exudation associated with allergic dermatitis.

    Time frame: 14 dyas

  6. Evaluate, through clinical examinations, the effectiveness of the drug association in reducing of scabbing associated with allergic dermatitis.

    Time frame: 14 days

  7. Evaluate, through clinical examinations, the effectiveness of the drug association in reducing of lichenification associated with allergic dermatitis.

    Time frame: 14 days

  8. Evaluate the safety of the formulations in relation to the occurrence, type, frequency and intensity of adverse events during treatment.

    Time frame: 14 days

07

Study locations

2 sites
  • LAL Clinica Pesquisa e Desenvolvimento Ltda
    Valinhos, São Paulo 13276-245, Brazil
  • LAL Clínica Pesquisa e Desenvolvimento Ltda
    Valinhos, São Paulo 13276-245, Brazil
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2010
First posted
May 18, 2010
Start
Nov 2010
Primary completionEst.
Nov 2010
Completion
Nov 2010
Last update
Nov 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01125761
Lead sponsor
Azidus Brasil
Responsible party
Azidus Brasil (Principal Investigator Dr. Alexandre Frederico, Azidus Brasil) — Principal investigator
First posted
May 18, 2010
Start date
Nov 2010
Primary completion
Nov 2010 (estimated)
Completion
Nov 2010
Last update
Nov 3, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion